The Leland Stanford Junior University (Stanford University) has been awarded a $411,206 Project Grant from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and evaluate an innovative radiopharmaceutical, [18F]HGTS13, as a non-invasive molecular imaging marker for monitoring ferroptosis, a form of cancer cell death, in cell culture and preclinical models. The project aims to establish [18F]HGTS13 PET imaging as a tool to identify cancers susceptible to ferroptosis-inducing therapies and track the engagement and efficacy of such treatments. The award period runs from July 2024 through June 2029. If successful, this research could provide important advances in the use of ferroptosis induction as a cancer treatment strategy and leverage molecular imaging to guide personalized therapy selection.
Generated 1/28/25, 7:35 AM